Centiva Capital’s Forte Biosciences FBRX Stock Holding History

Centiva Capital’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-424	Closed	-$31K	–	1307
2021 Q3	$31K	Buy	+424	New	+$235K	﹤0.01%	1164

Other funds holding FBRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Centiva Capital's FBRX Position: Q4 2021 in Review

Centiva Capital sold out of Forte Biosciences (FBRX) in Q4 2021, closing a stake of 424 shares — an estimated $31K sold.

Centiva Capital first reported a position in FBRX in Q3 2021 and held it in 1 quarter. The position peaked at $31K in Q3 2021. 52 funds tracked by Wall St. Rank hold FBRX as of Q4 2021.

Centiva Capital reported no remaining Forte Biosciences position as of Q4 2021 after selling out during the quarter.
Centiva Capital sold 424 Forte Biosciences shares in Q4 2021, an estimated $31K.
Centiva Capital first reported a position in Forte Biosciences in Q3 2021 and held it in 1 quarter.
Centiva Capital's Forte Biosciences position peaked at $31K in Q3 2021.
52 funds tracked by Wall St. Rank held Forte Biosciences as of Q4 2021.

Based on Centiva Capital's 13F filing for Q4 2021, filed 14 Feb 2022.